Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.

Abstract:

:A phase I study of S-1 and biweekly docetaxel (DOC) combination therapy was conducted to determine the maximum tolerated dose (MTD) and pharmacokinetic parameters. Fourteen patients with advanced or recurrent gastric cancer were analyzed. The treatment consisted of S-1 [body surface area (BSA) <1.25 m2:80 mg/day, 1.25

journal_name

Oncol Rep

journal_title

Oncology reports

authors

Takahashi I,Emi Y,Kakeji Y,Tokunaga E,Ushiro S,Oki E,Watanabe M,Baba H,Maehara Y

keywords:

subject

Has Abstract

pub_date

2006-04-01 00:00:00

pages

849-54

issue

4

eissn

1021-335X

issn

1791-2431

journal_volume

15

pub_type

杂志文章